Related Experiment Videos
The "develOpment of metabolic and functional markers of Dementia IN Older people" (ODINO) Study: Rationale, Design
Anna Picca1, Daniela Ronconi2, Hélio J Coelho-Junior2
1Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, 00168 Rome, Italy.
Abstract:
Mild cognitive impairment (MCI), also termed mild neurocognitive disorder, includes a heterogeneous group of conditions characterized by declines in one or more cognitive domains greater than that expected during "normal" aging but not severe enough to impair functional abilities. MCI has been associated with an increased risk of developing dementia and even considered an early stage of it. Therefore, noninvasively accessible biomarkers of MCI are highly sought after for early identification of the condition. Systemic inflammation, metabolic perturbations, and declining physical performance have been described in people with MCI. However, whether biological and functional parameters differ across MCI neuropsychological subtypes is presently debated. Likewise, the predictive value of existing biomarkers toward MCI conversion into dementia is unclear. The "develOpment of metabolic and functional markers of Dementia IN Older people" (ODINO) study was conceived as a multi-dimensional investigation in which multi-marker discovery will be coupled with innovative statistical approaches to characterize patterns of systemic inflammation, metabolic perturbations, and physical performance in older adults with MCI. The ultimate aim of ODINO is to identify potential biomarkers specific for MCI subtypes and predictive of MCI conversion into Alzheimer's disease or other forms of dementia over a three-year follow-up. Here, we describe the rationale, design, and methods of ODINO.
Insights
The ODINO study investigates mild cognitive impairment (MCI) biomarkers. Researchers aim to identify markers for MCI subtypes and predict dementia conversion in older adults.
Area of Science:
- Neuroscience
- Gerontology
- Biomarker Discovery
Background:
- Mild cognitive impairment (MCI) is a heterogeneous condition with cognitive declines exceeding normal aging, increasing dementia risk.
- Early identification of MCI is crucial, necessitating accessible, noninvasive biomarkers.
- Existing research on biological and functional parameters across MCI subtypes and biomarker predictive value for dementia conversion remains unclear.
Purpose of the Study:
- To characterize patterns of systemic inflammation, metabolic perturbations, and physical performance in older adults with MCI.
- To identify potential biomarkers specific for MCI subtypes.
- To determine biomarkers predictive of MCI conversion to Alzheimer's disease or other dementias over a three-year follow-up.
Main Methods:
- The ODINO study employs a multi-dimensional investigation approach.
- Multi-marker discovery is combined with innovative statistical methods.
- Data collection focuses on systemic inflammation, metabolic perturbations, and physical performance in older adults with MCI.
Main Results:
- This section will present findings on biomarker patterns in MCI subtypes.
- Results will detail the predictive value of identified biomarkers for dementia conversion.
- The study will elucidate differences in biological and functional parameters across MCI subtypes.
Conclusions:
- The ODINO study aims to establish novel biomarkers for MCI subtypes.
- Findings will contribute to predicting MCI progression to dementia, including Alzheimer's disease.
- This research will advance early detection and personalized management strategies for cognitive decline.
Related Concept Videos
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:30Dementia
The progression of dementia is generally gradual....